Task B1: Phase I Clinical Trial to Evaluate a Therapeutic for Antibiotic Resistant Gram Negative and Positive Bacterial Infections

NIH RePORTER · NIH · N01 · $284,064 · view on reporter.nih.gov ↗

Abstract

The Phase I Clinical Trial Units provide a vehicle for the investigation of new therapeutic and immunomodulatory agents for the treatment of infectious disease.

Key facts

NIH application ID: 11142290
Project number: 272201500005I-P00009-759302100202-1
Recipient: DYNPORT VACCINE COMPANY, LLC
Principal Investigator: GRAIG SHOCKEY
Activity code: N01
Funding institute: NIH
Fiscal year: 2024
Award amount: $284,064
Award type: —
Project period: 2021-05-13 → 2024-12-31